Therapeutic solutions for neurodegeneration

There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.

Alzprotect designs and develops innovative therapeutic solutions for these diseases.

Our objective: to slow down or stop neurodegeneration and, where possible, to restore some brain capacities

 Learn more about Alzprotect 

An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.

Schematic diagram of the action of AZP2006

Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.

Learn more about
AZP2006 molecule


Alzprotect and the Rothschild Foundation Hospital announce the signing of a collaboration in a phase 2 clinical trial for the treatment of Progressive Supranuclear Palsy

Lille (France), May 11th - Alzprotect, biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases, and the Adolphe de Rothschild Foundation Hospital announced today the signing of a collaboration agreement. This first materializes with the opening in Paris, within the Rothschild Foundation Hospital of the 3rd clinical center, as part of the phase 2a trial aimed at evaluating the safety of the main drug candidate of the company, EZEPROGIND (AZP2006) for the treatment of progressive supranuclear palsy (PSP). PSP is an orphan disease for which Alzprotect has obtained "orphan drug" status from the Food and Drug Administration (FDA) and the European Medicines Agency. Alzprotect is financed by the Xerys funds.

With EZEPROGIND, Alzprotect mainly targets two neurodegenerative diseases: Progressive Supranuclear Palsy (PSP) for which there is no treatment to date and Alzheimer's disease, recognized as a major public health issue, currently without any reliable early diagnosis or treatment that can modify the course of the disease.

Dr Pierre Le Sourd, member of the Supervisory Board of Xerys Gestion and member of the Board of Directors of Alzprotect, declares “It is our duty at Xerys to invest in companies whose mission is to identify solutions for diseases that are public health priorities. We are proud of this scientific partnership with the Adolphe de Rothschild Foundation Hospital. This is a very strong signal. I would like to thank Mr. Julien Gottsmann as well as all the teams who make it possible to accelerate this project to fight neurodegenerative diseases. "

Monsieur Julien Gottsmann, CEO of the Rothschild Foundation Hospital emphasizes: "The signing of this agreement with the biotechnology company Alzprotect will allow us to jointly conduct a clinical trial to evaluate a treatment against Progressive Supranuclear Palsy. This partnership signed within the framework of Rothschild Medical Development brings hope for treatments to patients suffering from PSP. "

 Dr Michael Alexandre Obadia, neurologist at the Rothschild Foundation Hospital adds: "Supra-nuclear paralysis is a severe pathology with a poor prognosis; the development of new therapies is a major issue in this field. I look forward to participating in this ambitious project on behalf of the Hospital and the collaboration that is beginning with the Alzprotect teams. "

Dr Philippe Verwaerde, President of Alzprotect, said: “We are very excited to start this collaboration and to benefit from the internationally recognized expertise of the Rothschild Foundation Hospital and its teams in the field of neurology. The hospital is also monitoring a large number of PSP patients, which will allow us to complete our phase 2a study, and hopefully continue to develop our scientific collaboration. "

Alzprotect Establishes US Subsidiary

Lille (France), April 8th, 2021 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today today hat it has established its US based subsidiary, Alzprotect US Inc. in Boston, Massachusetts, in line with its international development strategy.

This new subsidiary of Alzprotect is situated in Boston. The world’s ten largest biopharma companies have a presence in Massachusetts, making it an ideal location for scientific and technological innovation and ideally suited for Alzprotect’ first US foothold.

The creation of this affiliate is the first milestone in a process that will lead to the initiation of Alzprotect’ clinical trials for the treatment of PSP and Alzheimer’s disease in the US.

Dr Philippe Verwaerde, CEO of Alzprotect, commented: “The creation of a subsidiary in the US is an important step forward in our strategy as set out in our future development. This further strengthens the international reach of our innovative pipeline for the treatment of neurodegeneration. We are very excited to become part of the biotechnology cluster in Cambridge and believe this prime location will prove to be extremely beneficial to the Company as we move our clinical development forward in this important market.”


All news